Axitinib

Almost white powder;

Purity:98.0-105.0%

Multi-targeted small molecule inhibitors, the main targets are VEGFR, Kit, PDGFR (multi-targeted, anti-angiogenesis-based small molecule inhibitors, basically these are the targets, and some can also inhibit MET, such as cabozantinib).

Second-line treatment for advanced kidney cancer.